<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5948">
  <stage>Registered</stage>
  <submitdate>16/03/2016</submitdate>
  <approvaldate>16/03/2016</approvaldate>
  <nctid>NCT02719990</nctid>
  <trial_identification>
    <studytitle>Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in AGHD</studytitle>
    <scientifictitle>An Open-Label, Long-Term Extension Study of the Safety of Somavaratan (VRS-317) in Adults With Growth Hormone Deficiency (GHD)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>15VR8</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Adult Growth Hormone Deficiency (AGHD)</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other endocrine disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - somavaratan

Experimental: Somavaratan in adults with GHD - Cohort 1: Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly in adult subjects with GHD irrespective of age and gender

Experimental: Somavaratan in women on estrogen - Cohort 2: Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly in adult female subjects with GHD on oral estrogen (regardless of age)


Treatment: drugs: somavaratan
Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety as measured by the number of subjects with adverse events, concomitant medications, safety labs, vital signs and physical exams - Safety observations include adverse events, concomitant medications, safety labs, vital signs and physical exams</outcome>
      <timepoint>up to first 5 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety as measured by the number of subjects with adverse events, concomitant medications, safety labs, vital signs and physical exams - Safety observations include adverse events, concomitant medications, safety labs, vital signs and physical exams</outcome>
      <timepoint>up to 4 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Immunogenicity of VRS-317 by measurement and characterization of serum anti-drug antibody (ADA) titers - To evaluate the immunogenicity of VRS-317 by measurement and characterization of serum anti-drug antibody (ADA) titers</outcome>
      <timepoint>Quarterly for up to 4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacodynamics of VRS-317 by measurement of serum Insulin-like Growth Factor-1 (IGF-1) and Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) - To evaluate the pharmacodynamics of VRS-317 by measurement of serum Insulin-like Growth Factor-1 (IGF-1) and Insulin-like Growth Factor Binding Protein-3 (IGFBP-3)</outcome>
      <timepoint>Quarterly for up to 4 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluation of the starting dose and dose titration plan - To evaluate the starting dose and the dose titration plan of twice-monthly somavaratan during the titration phase of treatment</outcome>
      <timepoint>Monthly for 5 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluation of the maintenance dose and dose titration plan - To evaluate the maintenance dose and the dose titration plan of twice-monthly somavaratan during long-term treatment</outcome>
      <timepoint>Quarterly for up to 4 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Female subjects of childbearing potential must have negative pregnancy test and use
             appropriate contraceptive methods

          -  Documented GHD during adulthood

          -  Subjects naive to somavaratan must have an IGF-1 SDS value = 0 at Screening

          -  Subjects taking other hormone replacement therapy must have been on a stable course of
             treatment for at least 3 months

          -  Underlying disorders responsible for the subject's GHD must have been clinically
             stable for at least 6 months

          -  Subjects receiving daily rhGH injections must washout for = 14 days

          -  BMI (kg/m2) between 18.0 and 40.0</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Untreated adrenal insufficiency

          -  Recently diagnosed thyroid dysfunction which is not being treated or has not been
             stable on therapy for at least 3 months

          -  Currently taking anti-inflammatory dose of glucocorticoids that could potentially
             compromise safety or efficacy assessments

          -  Currently taking a GHRH or IGF-I product

          -  Current significant cardiovascular disease, heart insufficiency of New York Heart
             Association (NYHA) class &gt; 2

          -  Current significant disease thought to increase risk of receiving growth hormone or
             confound assessment of study outcomes

          -  History of diabetes mellitus or inadequate glucose control

          -  Current drug or alcohol abuse

          -  Current HIV wasting syndrome (HIV testing not required)

          -  History of malignancy in adulthood (subjects with a history of childhood malignancy
             that were subsequently treated with rhGH in childhood and remain GHD in adulthood may
             be enrolled)

          -  Women who are pregnant or breastfeeding

          -  Treatment with an investigational drug other than somavaratan within 30 days prior to
             Screening

          -  A significant abnormality in Screening laboratory results</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>250</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>St Vincent's Hospital - Fitzroy</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>3004 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Versartis Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Premier Research Group plc</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Open-label extension study to evaluate the safety of long-term twice-monthly administration
      of somavaratan in adults with Growth Hormone Deficiency (GHD).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02719990</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Daniela Rogoff, MD, PhD</name>
      <address>Versartis Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Eric Humphriss, MBA</name>
      <address />
      <phone>1-650-963-8587</phone>
      <fax />
      <email>ehumphriss@versartis.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>